EPISODE · Jul 24, 2026 · 9 MIN
GLP-1受体激动剂在肝病治疗的前沿进展
from 消化肝病前沿资讯
本期播客聚焦GLP-1受体激动剂在肝脏疾病治疗的前沿进展，从FDA加速批准Wegovy用于MASH，到与resmetirom的机制差异与联合潜力，再到破除‘仅靠减肥’误解、发现肝窦状隙内皮细胞新靶点，以及在酒精相关肝病中的奖赏环路与代谢保护作用。节目还探讨了MetALD患者的双重获益可能、最新诊疗指南更新及加速审批后续验证，展现GLP-1药物从代谢病跨向多病种协同治疗的广阔前景。00:06GLP-1药引肝病治疗革命00:55两药机制不同可联合探讨02:01破除减肥即疗效常见误解02:52新靶点证直接护肝作用03:49试验证多指标改善超预期04:54助力减酒瘾并护肝减毒05:40指南纳入个体化治MetALD06:28两药加速批待临床验证07:16从无助到多药现一药多效08:15新靶点或刷新机制认知09:21慢病需综合创新治疗
Embed this episode
NOW PLAYING
GLP-1受体激动剂在肝病治疗的前沿进展
0:00
9:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 消化肝病前沿资讯?
This episode is 9 minutes long.
When was this 消化肝病前沿资讯 episode published?
This episode was published on July 24, 2026.
Can I download this 消化肝病前沿资讯 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!